Search results

Skip to results

Type

Status

Last updated

Showing 1 to 2 of 2 results for eladocagene exuparvovec

  1. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST26

  2. NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder

    The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE.

    News
    Last updated
    19 January 2024